ABITRAM

Across TCGA pan-cancer cohorts, ABITRAM mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ABITRAM data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ABITRAM mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ABITRAM expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

HNSC, GBM, and LUAD are the cancer types where ABITRAM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.538	0.891	.001	11	view →
GBM	DFS	Tertile	All	0.498	0.221	.009	9	view →
LUAD	DFS	Median	II,III,IV	0.913	0.793	.019	6	view →
PDAC	OS	Median	II,III,IV	0.718	0.879	.022	6	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.684	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ABITRAM–HNSC (OS)

Open the HNSC breakdown →